Jazz Pharmaceuticals, Inc. (JAZZ) — 分析摘要
Jazz Pharmaceuticals, Inc.（JAZZ）的市值为14.89十亿美元，最近一年的营收同比增长了+4.9%。净利润率为-8.3%。当前市盈率为504.7倍。
核心要点
- 营收同比变化+4.9%
- 净利润率-8.3%
- 市盈率504.7倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，JAZZ的营收增长为+4.9%，市盈率为504.7倍。
Jazz Pharmaceuticals, Inc. (JAZZ)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 2119.0x — 高杠杆，存在再融资风险
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
2,890
总部
DUBLIN
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。